Traws Pharma (FRA:0T2) Net Income From Continuing Operations : €-17.59 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Traws Pharma's net income from continuing operations for the three months ended in Dec. 2023 was €-3.84 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-17.59 Mil.

Traws Pharma Net Income From Continuing Operations Historical Data

The historical data trend for Traws Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Net Income From Continuing Operations Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-19.35

-20.68

-14.30

-17.90

-17.38

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-5.12	-5.39	-3.92	-4.44	-3.84

Traws Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.59 Mil.

Traws Pharma (FRA:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ONTX:USA

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines